Elevation Oncology (ELEV) Competitors $0.38 +0.01 (+1.66%) Closing price 03:53 PM EasternExtended Trading$0.38 0.00 (0.00%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELEV vs. ENTX, IVVD, FBRX, CHRS, CLLS, CRBP, CLYM, ZNTL, JSPR, and EXOZShould you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Entera Bio (ENTX), Invivyd (IVVD), Forte Biosciences (FBRX), Coherus Oncology (CHRS), Cellectis (CLLS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), Jasper Therapeutics (JSPR), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry. Elevation Oncology vs. Its Competitors Entera Bio Invivyd Forte Biosciences Coherus Oncology Cellectis Corbus Pharmaceuticals Climb Bio Zentalis Pharmaceuticals Jasper Therapeutics eXoZymes Elevation Oncology (NASDAQ:ELEV) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings. Is ELEV or ENTX more profitable? Elevation Oncology has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. Elevation Oncology's return on equity of -74.68% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Elevation OncologyN/A -74.68% -48.14% Entera Bio -4,525.11%-95.10%-82.77% Which has better earnings and valuation, ELEV or ENTX? Entera Bio has higher revenue and earnings than Elevation Oncology. Entera Bio is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElevation OncologyN/AN/A-$44.49M-$0.82-0.47Entera Bio$180K492.38-$9.54M-$0.26-7.50 Does the media refer more to ELEV or ENTX? In the previous week, Elevation Oncology had 1 more articles in the media than Entera Bio. MarketBeat recorded 1 mentions for Elevation Oncology and 0 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.00 beat Elevation Oncology's score of -0.38 indicating that Entera Bio is being referred to more favorably in the news media. Company Overall Sentiment Elevation Oncology Neutral Entera Bio Neutral Which has more volatility and risk, ELEV or ENTX? Elevation Oncology has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Do analysts rate ELEV or ENTX? Elevation Oncology currently has a consensus price target of $3.39, indicating a potential upside of 779.41%. Entera Bio has a consensus price target of $10.00, indicating a potential upside of 412.82%. Given Elevation Oncology's higher possible upside, research analysts plainly believe Elevation Oncology is more favorable than Entera Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elevation Oncology 0 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in ELEV or ENTX? 83.7% of Elevation Oncology shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by company insiders. Comparatively, 10.4% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryElevation Oncology beats Entera Bio on 8 of the 15 factors compared between the two stocks. Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELEV vs. The Competition Export to ExcelMetricElevation OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.43M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.4721.4227.3820.03Price / SalesN/A285.81422.31120.16Price / CashN/A41.9536.6357.47Price / Book0.387.518.085.67Net Income-$44.49M-$55.05M$3.16B$248.47M7 Day PerformanceN/A3.16%2.12%2.90%1 Month Performance26.27%5.92%4.43%5.75%1 Year Performance-85.74%5.82%35.62%21.36% Elevation Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELEVElevation Oncology1.9371 of 5 stars$0.39+1.7%$3.39+779.4%-86.5%$22.43MN/A-0.4740ENTXEntera Bio2.6417 of 5 stars$1.90-4.0%$10.00+426.3%+11.7%$86.36M$223K-7.3120IVVDInvivyd3.1368 of 5 stars$0.72-1.6%$5.85+718.2%-34.3%$85.77M$25.38M-0.60100News CoverageGap UpFBRXForte Biosciences3.1081 of 5 stars$12.93+5.6%$61.00+371.8%+65,943.1%$85.08MN/A-0.795CHRSCoherus Oncology3.7438 of 5 stars$0.73-1.6%$4.68+540.4%-42.8%$84.78M$266.96M-0.65330News CoverageCLLSCellectis2.5396 of 5 stars$1.53+5.2%$4.00+162.3%-12.2%$84.77M$47.63M-1.77290News CoverageCRBPCorbus Pharmaceuticals3.7493 of 5 stars$6.90-6.8%$50.88+637.3%-83.9%$84.44MN/A-1.6440Negative NewsCLYMClimb Bio2.8378 of 5 stars$1.24+5.1%$9.00+625.8%N/A$83.80MN/A-0.529News CoveragePositive NewsZNTLZentalis Pharmaceuticals1.5886 of 5 stars$1.16-1.7%$8.37+621.3%-65.3%$83.46M$67.43M-0.37160JSPRJasper Therapeutics1.8953 of 5 stars$5.55+1.1%$59.25+967.6%-70.1%$83.36MN/A-1.0620Positive NewsEXOZeXoZymesN/A$9.88-4.9%N/AN/A$82.70M$70K0.0029News CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies ENTX Alternatives IVVD Alternatives FBRX Alternatives CHRS Alternatives CLLS Alternatives CRBP Alternatives CLYM Alternatives ZNTL Alternatives JSPR Alternatives EXOZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELEV) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
